These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33084440)

  • 21. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.
    Heidenreich S; Ziagkos D; de Wreede LC; van Biezen A; Finke J; Platzbecker U; Niederwieser D; Einsele H; Bethge W; Schleuning M; Beelen DW; Tischer J; Nagler A; Glass B; Maertens J; Yáñez L; Beguin Y; Sill H; Scheid C; Stelljes M; Ganser A; Zachée P; Selleslag D; de Witte T; Robin M; Kröger N
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):44-52. PubMed ID: 27720995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
    Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.
    Kaplan HG; Malmgren JA; Li CI; Calip GS
    Breast Cancer Res Treat; 2013 Dec; 142(3):629-36. PubMed ID: 24265034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
    Jonsdottir G; Björkholm M; Turesson I; Hultcrantz M; Diamond B; Porwit A; Landgren O; Kristinsson SY
    Eur J Haematol; 2021 Aug; 107(2):275-282. PubMed ID: 33966293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.
    Potter VT; Krishnamurthy P; Barber LD; Lim Z; Kenyon M; Ireland RM; de Lavallade H; Dhouri A; Marsh JC; Marcus R; Devereux S; Ho A; Pagliuca A; Mufti GJ
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):111-7. PubMed ID: 24216184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
    Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
    J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma.
    Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
    Cancer; 2010 Nov; 116(22):5279-89. PubMed ID: 20665502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
    Vaughn JE; Othus M; Powell MA; Gardner KM; Rizzuto DL; Hendrie PC; Becker PS; Pottinger PS; Estey EH; Walter RB
    JAMA Oncol; 2015 Nov; 1(8):1120-7. PubMed ID: 26355382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
    Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
    Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
    Freedman RA; Seisler DK; Foster JC; Sloan JA; Lafky JM; Kimmick GG; Hurria A; Cohen HJ; Winer EP; Hudis CA; Partridge AH; Carey LA; Jatoi A; Klepin HD; Citron M; Berry DA; Shulman LN; Buzdar AU; Suman VJ; Muss HB
    Breast Cancer Res Treat; 2017 Jan; 161(2):363-373. PubMed ID: 27866278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia.
    Mozessohn L; Cheung MC; Mittmann N; Earle CC; Liu N; Buckstein R
    JCO Oncol Pract; 2021 Apr; 17(4):e517-e525. PubMed ID: 32956005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals.
    Rieger CT; Cornely OA; Hoppe-Tichy T; Kiehl M; Knoth H; Thalheimer M; Schuler U; Ullmann AJ; Ehlken B; Ostermann H
    Mycoses; 2012 Nov; 55(6):514-20. PubMed ID: 22471310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group.
    Eichenauer DA; Thielen I; Haverkamp H; Franklin J; Behringer K; Halbsguth T; Klimm B; Diehl V; Sasse S; Rothe A; Fuchs M; Böll B; von Tresckow B; Borchmann P; Engert A
    Blood; 2014 Mar; 123(11):1658-64. PubMed ID: 24478403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
    Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
    Darrington DL; Vose JM; Anderson JR; Bierman PJ; Bishop MR; Chan WC; Morris ME; Reed EC; Sanger WG; Tarantolo SR
    J Clin Oncol; 1994 Dec; 12(12):2527-34. PubMed ID: 7989926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
    BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.
    Voso MT; Leone G; Piciocchi A; Fianchi L; Santarone S; Candoni A; Criscuolo M; Masciulli A; Cerqui E; Molteni A; Finelli C; Parma M; Poloni A; Carella AM; Spina F; Cortelezzi A; Salvi F; Alessandrino EP; Rambaldi A; Sica S
    Ann Oncol; 2017 Jul; 28(7):1547-1553. PubMed ID: 28368509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome.
    Chien SH; Yao M; Li CC; Chang PY; Yu MS; Huang CE; Tan TD; Lin CH; Yeh SP; Li SS; Wang PN; Liu YC; Gau JP
    J Formos Med Assoc; 2021 Dec; 120(12):2144-2152. PubMed ID: 33423899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.